On January 6, Shandong Sito Bio-Technology Co.Ltd(300583) (300583. SZ) shares rose 18.73% to 29.98 yuan / share at the opening, and closed at 27.79 yuan / share, up 10.06%.
However, from the perspective of capital, the main capital of the unit was in an outflow state on that day. On that day, the main capital inflow was 31.83 million yuan, the outflow was 32.49 million yuan, and the main capital net outflow was 661000 yuan.
On December 31, 2021, Shandong Sito Bio-Technology Co.Ltd(300583) announced that the controlling shareholder of the company, Shandong Runxin Investment Co., Ltd. (hereinafter referred to as “Shandong Runxin”), the actual controller Mi Chaojie and the concerted actor Mi Jia planned to transfer part of the company’s shares to strategic investors and other investors in the form of block transaction and agreement transfer, and reduce part of the company’s shares in the form of centralized bidding transaction, Total no more than 19841700 shares, no more than 18.5% of the company’s current total share capital.
It is reported that if the company reduces its holdings through centralized bidding trading at the stock exchange, it will be carried out within 6 months after 15 trading days from the date of the above announcement. If it reduces its holdings through block trading and agreement transfer, it will be carried out within 6 months after 3 trading days from the date of the announcement.
Shandong Sito Bio-Technology Co.Ltd(300583) said that the implementation of the reduction plan will not lead to changes in the company’s control and will not have an adverse impact on the company’s governance structure and sustainable operation. Public information shows that Shandong Runxin holds 39802720 shares of the company, accounting for 37.11% of the current total share capital of the company; Mi Chaojie holds 24.448 million shares of the company, accounting for 22.79% of the current total share capital of the company; Micah holds 1.8 million shares of the company, accounting for 1.68% of the total share capital of the company at present. It can be seen that even if Shandong Runxin, MI Chaojie and Mi Jia complete the reduction plan, their cumulative Shandong Sito Bio-Technology Co.Ltd(300583) shares are still 43.08%.
At present, Shandong Sito Bio-Technology Co.Ltd(300583) has not disclosed the strategic investors who will “take over” its shares, nor has it clearly disclosed the number of shares to be purchased by the relevant war investors. The interface news sent a call to the Securities Department of the company, and so far no reply has been received.
According to Shandong Sito Bio-Technology Co.Ltd(300583) , the main purpose of the controlling shareholder’s reduction is to “introduce strategic investors who recognize the inherent value of the company and are optimistic about future development, optimize the company’s ownership structure and promote the sustainable development of the company.”
However, another announcement disclosed on the same day as the reduction plan may reveal some information. On December 31 last year, Shandong Sito Bio-Technology Co.Ltd(300583) disclosed that Shandong Runxin, the controlling shareholder, handled the pledge deferred repurchase business for some shares of the listed company it held. The number of shares pledged to China Merchants Securities Co.Ltd(600999) was 8064000, accounting for 20.26% of the company’s shares and 7.52% of the total share capital of the listed company. According to the announcement, the maturity date of the pledge of these shares is December 31, 2021. Now it will be extended to December 31, 2022. The purpose of the pledge is to “support the production and operation of subsidiaries”.
Shandong Sito Bio-Technology Co.Ltd(300583) said that the delayed pledge of shares will not lead to the change of Shandong Runxin’s actual control over the listed company. According to its statement, Shandong Runxin has good capital repayment ability and sufficient risk control ability. At present, there is no risk of closing positions or being forced to close positions, which has no adverse impact on the production and operation, corporate governance and performance compensation obligations of the listed company; If the company’s share price fluctuates to the early warning line, Shandong Runxin will actively take countermeasures, including but not limited to supplementary pledge, additional margin or prepayment.
From the Shandong Sito Bio-Technology Co.Ltd(300583) situation, its operation has also been under great pressure in recent years. Public information shows that the company is committed to manufacturing steroidal drug raw materials by using genetic engineering technology and microbial transformation technology. It is an important supplier of steroidal drug raw materials by biotechnology in China; Since 2019, it has gradually laid out respiratory high-end characteristic APIs and preparation products. Some respiratory high-end characteristic APIs have obtained production licenses and successively entered the stage of related review. At present, it has the capacity of mass production of this part of APIs.
After landing in the A-share market in 2017, the performance of this listed company is not very stable. According to the financial data, from 2017 to 2020 and the first September of 2021, Shandong Sito Bio-Technology Co.Ltd(300583) realized the net profit attributable to the parent company of 92 million yuan, 127 million yuan, 55 million yuan, – 180 million yuan and 32 million yuan respectively.
Shandong Sito Bio-Technology Co.Ltd(300583) profitability since listing in 2017
As of September 30, 2021, Shandong Sito Bio-Technology Co.Ltd(300583) short-term borrowings reached 498 million yuan, accounts payable 302 million yuan, and the monetary capital on its account was 221 million yuan. Statistics show that the company’s asset liability ratio has continued to rise in recent years, from 15.68% in 2017 to 43.45% at the end of September 2021.
The capital pressure is increasing. In July 2021, Shandong Sito Bio-Technology Co.Ltd(300583) disclosed the latest fixed increase plan. It plans to issue no more than 32175770 shares to no more than 35 specific objects. It is expected to raise 300 million yuan to invest in high-end preparation industrialization projects and supplement working capital. However, after three rounds of inquiries, the maximum fund-raising amount of the company’s fixed increase in this round was reduced to 292 million yuan, and the fund-raising amount used to supplement working capital was reduced from 11.1296 million yuan to 3.289 million yuan. On January 5, 2022, Shandong Sito Bio-Technology Co.Ltd(300583) this round of fixed increase was approved by the listing audit center of Shenzhen Stock Exchange.
(interface News)
